Dimensional Fund Advisors LP Cuts Stock Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Dimensional Fund Advisors LP cut its holdings in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 31.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,923 shares of the company’s stock after selling 16,361 shares during the quarter. Dimensional Fund Advisors LP owned 0.11% of Actinium Pharmaceuticals worth $44,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Renaissance Technologies LLC increased its position in shares of Actinium Pharmaceuticals by 49.9% during the fourth quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock worth $240,000 after purchasing an additional 63,400 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Actinium Pharmaceuticals by 804.5% during the fourth quarter. JPMorgan Chase & Co. now owns 123,831 shares of the company’s stock worth $156,000 after purchasing an additional 110,141 shares in the last quarter. Sei Investments Co. purchased a new stake in shares of Actinium Pharmaceuticals during the fourth quarter worth approximately $62,000. Creative Financial Designs Inc. ADV increased its position in shares of Actinium Pharmaceuticals by 42.7% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 91,007 shares of the company’s stock worth $115,000 after purchasing an additional 27,222 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its position in shares of Actinium Pharmaceuticals by 25.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after purchasing an additional 42,770 shares in the last quarter. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on ATNM. StockNews.com cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 12th. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday, May 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $4.00.

Actinium Pharmaceuticals Stock Up 9.2%

Shares of ATNM opened at $1.67 on Monday. Actinium Pharmaceuticals, Inc. has a 52-week low of $1.03 and a 52-week high of $9.87. The company has a market capitalization of $52.10 million, a PE ratio of -1.20 and a beta of -0.24. The stock has a fifty day simple moving average of $1.39 and a two-hundred day simple moving average of $1.34.

Actinium Pharmaceuticals Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).